JP7832945B2 - Irak分解剤およびそれらの使用 - Google Patents

Irak分解剤およびそれらの使用

Info

Publication number
JP7832945B2
JP7832945B2 JP2023534948A JP2023534948A JP7832945B2 JP 7832945 B2 JP7832945 B2 JP 7832945B2 JP 2023534948 A JP2023534948 A JP 2023534948A JP 2023534948 A JP2023534948 A JP 2023534948A JP 7832945 B2 JP7832945 B2 JP 7832945B2
Authority
JP
Japan
Prior art keywords
alkyl
aliphatic
ring
optionally substituted
independently selected
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2023534948A
Other languages
English (en)
Japanese (ja)
Other versions
JP2023552827A5 (cg-RX-API-DMAC7.html
JP2023552827A (ja
Inventor
シャオジャン ジェン,
シャオ ジュー,
Original Assignee
カイメラ セラピューティクス, インコーポレイテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by カイメラ セラピューティクス, インコーポレイテッド filed Critical カイメラ セラピューティクス, インコーポレイテッド
Publication of JP2023552827A publication Critical patent/JP2023552827A/ja
Publication of JP2023552827A5 publication Critical patent/JP2023552827A5/ja
Application granted granted Critical
Publication of JP7832945B2 publication Critical patent/JP7832945B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/545—Heterocyclic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/55—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound the modifying agent being also a pharmacologically or therapeutically active agent, i.e. the entire conjugate being a codrug
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Liquid Crystal Substances (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Steroid Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
JP2023534948A 2020-12-09 2021-12-09 Irak分解剤およびそれらの使用 Active JP7832945B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202063123330P 2020-12-09 2020-12-09
US63/123,330 2020-12-09
PCT/US2021/062640 WO2022125790A1 (en) 2020-12-09 2021-12-09 Irak degraders and uses thereof

Publications (3)

Publication Number Publication Date
JP2023552827A JP2023552827A (ja) 2023-12-19
JP2023552827A5 JP2023552827A5 (cg-RX-API-DMAC7.html) 2024-12-17
JP7832945B2 true JP7832945B2 (ja) 2026-03-18

Family

ID=81973811

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2023534948A Active JP7832945B2 (ja) 2020-12-09 2021-12-09 Irak分解剤およびそれらの使用

Country Status (13)

Country Link
US (2) US20230096599A1 (cg-RX-API-DMAC7.html)
EP (1) EP4259128A4 (cg-RX-API-DMAC7.html)
JP (1) JP7832945B2 (cg-RX-API-DMAC7.html)
KR (1) KR20230130179A (cg-RX-API-DMAC7.html)
CN (1) CN116669722A (cg-RX-API-DMAC7.html)
AR (1) AR124294A1 (cg-RX-API-DMAC7.html)
AU (1) AU2021396308A1 (cg-RX-API-DMAC7.html)
CA (1) CA3200608A1 (cg-RX-API-DMAC7.html)
CO (1) CO2023006818A2 (cg-RX-API-DMAC7.html)
IL (1) IL303458A (cg-RX-API-DMAC7.html)
MX (1) MX2023006719A (cg-RX-API-DMAC7.html)
TW (1) TW202237601A (cg-RX-API-DMAC7.html)
WO (1) WO2022125790A1 (cg-RX-API-DMAC7.html)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL315310A (en) 2017-12-26 2024-10-01 Kymera Therapeutics Inc Irak degraders and uses thereof
AU2019389174A1 (en) 2018-11-30 2021-07-01 Kymera Therapeutics, Inc. Irak degraders and uses thereof
PH12022500002A1 (en) 2019-06-28 2023-04-03 Kymera Therapeutics Inc Irak degraders and uses thereof
US12558427B2 (en) 2019-07-17 2026-02-24 Kymera Therapeutics, Inc. IRAK degraders and uses thereof
WO2021119159A1 (en) 2019-12-10 2021-06-17 Kymera Therapeutics, Inc. Irak degraders and uses thereof
CA3161878A1 (en) 2019-12-17 2021-06-24 Matthew M. Weiss Irak degraders and uses thereof
AR124547A1 (es) 2020-12-30 2023-04-05 Kymera Therapeutics Inc Degradadores de irak y sus usos
EP4393922A4 (en) * 2021-08-23 2026-01-28 Leadingtac Pharmaceutical Shaoxing Co Ltd IRAK4 DEGRADATION AGENT, ITS PREPARATION PROCESS AND ITS USE
EP4472967A4 (en) 2022-01-31 2026-04-15 Kymera Therapeutics Inc Iraqi Degradation Agents and Their Uses
WO2024020084A1 (en) * 2022-07-20 2024-01-25 Bristol-Myers Squibb Company Heteroaryl compounds as ligand directed degraders of irak4
KR20260048566A (ko) * 2023-07-13 2026-04-10 인크레랜드 방향족 화합물, 이를 포함하는 약제학적 조성물 및 이의 용도
EP4759807A1 (en) 2023-08-11 2026-06-17 Shenzhen Zhongge Biological Technology Co., Ltd. Proteolysis targeting chimera compound for degrading irak4 and use thereof
EP4775569A1 (en) * 2023-09-08 2026-07-15 The Global Health Drug Discovery Institute 3cl protease inhibitor for treating or preventing coronavirus infections and use thereof
WO2025108406A1 (zh) * 2023-11-22 2025-05-30 广东东阳光药业股份有限公司 一种靶向降解雄激素受体的双功能嵌合体的杂环化合物及其用途
WO2025168131A1 (zh) * 2024-02-08 2025-08-14 清华大学 一种多靶降解剂及其用途
WO2026136763A1 (en) 2024-12-19 2026-06-25 Bristol-Myers Squibb Company Genetic predictor for il18 driven disease
WO2026136866A1 (en) 2024-12-20 2026-06-25 Prelude Therapeutics Incorporated Kat6 targeting compounds

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2019099926A1 (en) 2017-11-17 2019-05-23 Arvinas, Inc. Compounds and methods for the targeted degradation of interleukin-1 receptor-associated kinase 4 polypeptides
WO2019133531A1 (en) 2017-12-26 2019-07-04 Kymera Therapeutics, Inc. Irak degraders and uses thereof
WO2020113233A1 (en) 2018-11-30 2020-06-04 Kymera Therapeutics, Inc. Irak degraders and uses thereof
JP2022548095A (ja) 2019-09-16 2022-11-16 ノバルティス アーゲー 接着分解剤及びその使用方法
JP2023518423A (ja) 2020-03-19 2023-05-01 カイメラ セラピューティクス, インコーポレイテッド Mdm2分解剤およびそれらの使用

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW201728592A (zh) * 2012-01-10 2017-08-16 林伯士艾瑞斯公司 Irak抑制劑及其用途
HK1254469A1 (zh) * 2015-06-26 2019-07-19 Dana Farber Cancer Institute, Inc. 稠合双环嘧啶衍生物及其用途
WO2017007612A1 (en) * 2015-07-07 2017-01-12 Dana-Farber Cancer Institute, Inc. Methods to induce targeted protein degradation through bifunctional molecules
WO2017185031A1 (en) * 2016-04-22 2017-10-26 Dana-Farber Cancer Institute, Inc. Degradation of cyclin-dependent kinase 4/6 (cdk4/6) by conjugation of cdk4/6 inhibitors with e3 ligase ligand and methods of use
US12454520B2 (en) * 2018-07-06 2025-10-28 Kymera Therapeutics, Inc. Protein degraders and uses thereof

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2019099926A1 (en) 2017-11-17 2019-05-23 Arvinas, Inc. Compounds and methods for the targeted degradation of interleukin-1 receptor-associated kinase 4 polypeptides
WO2019133531A1 (en) 2017-12-26 2019-07-04 Kymera Therapeutics, Inc. Irak degraders and uses thereof
WO2020113233A1 (en) 2018-11-30 2020-06-04 Kymera Therapeutics, Inc. Irak degraders and uses thereof
JP2022548095A (ja) 2019-09-16 2022-11-16 ノバルティス アーゲー 接着分解剤及びその使用方法
JP2023518423A (ja) 2020-03-19 2023-05-01 カイメラ セラピューティクス, インコーポレイテッド Mdm2分解剤およびそれらの使用

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
NUNES, Joao et al.,"Targeting IRAK4 for Degradation with PROTACs",ACS Medicinal Chemistry Letters,2019年,2019, 10,1081-1085

Also Published As

Publication number Publication date
EP4259128A1 (en) 2023-10-18
IL303458A (en) 2023-08-01
EP4259128A4 (en) 2025-04-30
AU2021396308A9 (en) 2025-03-20
US20230096599A1 (en) 2023-03-30
KR20230130179A (ko) 2023-09-11
AU2021396308A1 (en) 2023-06-22
CA3200608A1 (en) 2022-06-16
AR124294A1 (es) 2023-03-15
TW202237601A (zh) 2022-10-01
CN116669722A (zh) 2023-08-29
CO2023006818A2 (es) 2023-07-10
US20250375526A1 (en) 2025-12-11
WO2022125790A1 (en) 2022-06-16
MX2023006719A (es) 2023-06-23
JP2023552827A (ja) 2023-12-19

Similar Documents

Publication Publication Date Title
US12539295B2 (en) IRAK degraders and uses thereof
US11591332B2 (en) IRAK degraders and uses thereof
US12558427B2 (en) IRAK degraders and uses thereof
US20230089916A1 (en) Irak degraders and uses thereof
US20250375526A1 (en) Irak degraders and uses thereof
WO2021158634A1 (en) Irak degraders and uses thereof
WO2022147465A1 (en) Irak degraders and uses thereof
AU2021240046A1 (en) MDM2 degraders and uses thereof
WO2020251969A1 (en) Smarca degraders and uses thereof
KR20240144266A (ko) Irak 분해제 및 이의 용도
WO2019133531A1 (en) Irak degraders and uses thereof
EP4072591A1 (en) Irak degraders and uses thereof
JP2023509394A (ja) Smarca分解剤およびそれらの使用
WO2023220425A1 (en) Bcl-xl/bcl-2 degraders and uses thereof
WO2024092011A1 (en) Irak degraders and uses thereof

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20241209

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20241209

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20250926

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20251104

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20260203

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20260212

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20260306

R150 Certificate of patent or registration of utility model

Ref document number: 7832945

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150